Clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) announced on Monday that it has received an official Filing Receipt from the United States Patent and Trademark Office (USPTO) for a new patent application related to the proprietary formulation of its lead clinical asset, HT-001.

This newly filed application seeks to expand the company's intellectual property portfolio surrounding HT-001 and builds upon Hoth's already approved patent for the compound.

The formulation-specific filing is aimed at further protecting the unique composition and delivery method of HT-001, which is being developed as a novel topical treatment to alleviate dermatologic side effects commonly experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor therapy.